Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Sweden
Finland
Denmark
Norway
Latest
Trending
Followed

CellaVision, Audiocast, Q2'26

By Inderes7/17/2026, 9:00 AM
CellaVision

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Steve Ferguson
00:01 - 04:24

Good morning, everyone, and thank you for joining us today. My name is Steve Ferguson, and with me is our Chief Financial Officer, Monica Johnson. We appreciate you taking the time to join us this morning as we present CellaVision's results for the second quarter of 2026. Following the presentation, both Monica and I will be happy to take questions. As this is my first quarterly earnings call since joining CellaVision as CEO on June 5th, I would also like to take a moment to very briefly introduce myself. I spent more than 25 years in international leadership roles across the life science, diagnostic, and healthcare industries. Most recently, I served as CEO of Medix Biochemica in Finland. Following senior commercial and operational leadership positions at Thermo Fisher Scientific or Phadia in Uppsala, and prior to that with Lundbeck based in Copenhagen. I am very excited to be part of CellaVision and to the challenge ahead, and I look forward to working together with our very talented team, our partners, and all of you as we continue to build on the company's strong foundation to advance laboratory workflow and diagnostic certainty through intelligent microscopy. I am speaking to you this morning from Vancouver, where it is 2 a.m. I will do my best to keep our energy high during this call. With that, let's turn to our second quarter results. CellaVision's second quarter represents a solid performance and a recovery from the slower start to the year. The quarter resulted in net sales of 200 MSEK, an increase of 4.5% over quarter two 2025. Sales increased organically by 5.6%, where we saw a 1.1% headwind in currency, and EBITDA for the period amounted to 55 million SEK, which corresponds to a 27% EBITDA margin. EBITDA for the second quarter was charged with expenses of 9 million SEK associated with the initial costs of the CEO transition. Adjusted for these expenses, the EBITDA increased compared to the same quarter last year. As we highlight in the report, Americas reached an all-time high in sales fueled by large instruments, and this was driven by the accelerated workflow uptake among midsize and large laboratory networks. EMEA showed a stable result, but was still slightly affected by the now-concluded inventory adjustment from our main distributor partner. And finally, in APAC, we maintained a steady development, though market conditions remain challenging, particularly in China. We see a notable uptake of the reagent business in both Japan and Australia, along with a tender win for the United Nations. The commercial launch of our Bone Marrow Aspirate (BMA) application in EMEA marks an important milestone in our expansion into specialized microscopy. Initial customer interest and sales have been encouraging, reinforcing our confidence in this market opportunity and demonstrating our ability to translate our innovation and our R&D investments into commercial results. We continue to progress outside of Europe with the FDA registration process for the Bone Marrow Aspirate (BMA) Application, with our aim of obtaining 510(k) market clearance in the US before year-end. And finally, the development of the Fourier Ptychographic Microscopy (FPM) technology continues to progress through our development phases, forming the foundation of our next-generation Hematology analyzers. And this strengthens our confidence in FPM as a platform technology for future innovation beyond Hematology. These are exciting developments for CellaVision. And right now, let me hand over to Monica to present an overview of the financial development during quarter two, 2026.

Monica Johnson
04:27 - 07:12

Thanks. Let's unpack the P&L and cash flow. Net sales were 200 million SEK in the quarter, representing 4% growth, or 6% organic growth, against the same quarter last year. We had a gross margin of 70%, and that entails also an increase in our amortization of capitalized development expenditures for Bone Marrow Aspirate (BMA) Application, and also the upgraded software program that we are amortizing throughout the full quarter. And here we are now amortizing 4 million versus 2 million last year. Operating expenses landed at 100 million SEK, equaling 50% of net sales. And if we unpack that, we see that sales and marketing expenses are kept on a stable level. Administration expenses were impacted by the costs of 9 million SEK associated with the initial phase of the CEO transition. R&D costs before capitalization were 45 million, just a little higher than last year. However, comparing to the same quarter last year, we have a lower capitalization of 5 million versus 20 million SEK the last year, and that results in an R&D cost of 30 million SEK. The lower capitalization is mainly due to different maturity stages of our ongoing projects, and we expect to see some increase in capitalization from Q3 as projects are maturing. The EBITDA reached 55 million SEK with an EBITDA margin of 27%, and the increased operating expenses related to the initial phase of the CEO transition, of course, impacted these results. Adjusted for this, EBITDA and EBITDA margin increased compared to the same quarter last year. We are continuing to invest in R&D, which accounts for 22% of net sales. R&D investment programs are developing well and maturing according to plan. Finally, operating cash flow was 29 million SEK. Working capital increased by 32 million SEK during the quarter. Accounts receivable increased as a result of the higher sales and contributed negatively to cash flow, as did the increased capital tied up in inventory in preparation for the summer break. Total cash flow of -58 million SEK for the quarter included a dividend to the shareholders of 66 million SEK, and our financial position remains robust, with cash and cash equivalents of 172 million SEK. We have a strong cash position sitting on the balance sheet. And let's go into the regional development.

Steve Ferguson
07:18 - 13:44

Thank you, Monica. So, just to provide a quick comment on the business by region. So if we look first at the Americas, this is an all-time record high quarter driven, as I said earlier, by large instrument sales, tender wins, and instrument refreshes, and sales increased to 105 million SEK, up from 66 million SEK last year. And really, this is a reflection of our strong partnership in the US. Our sales here are really being driven by robust demand in the large and medium-sized laboratory segments, but it is also boosted by strong order books in Canada and Latin America, and this reflects excellent marketing and commercial activities that have been carried out in the run-up to the second quarter. This year in EMEA, sales amounted to 75 million SEK, which is slightly down compared to last year. Here we see the full impact of the now concluded inventory adjustment from our main distribution partner, and we are confident that the inventory adjustment has now been fully executed. The Bone Marrow Aspirate (BMA) Application launch that I referred to earlier has generated initial sales and a lot of positive customer interest, with commercial activities supporting customer evaluations at numerous sites. These activities have remained high throughout the quarter, supported by our presence at key industry events. And it should be noted that instrument sales in EMEA are above quarter one and above the same quarter last year. For APAC, sales amounted to 19 million SEK, significantly below quarter 2, 2025. Now, on the face of it, this looks extremely disappointing. However, there are underlying positives here. We see the double impact from China, where market conditions remain challenging for current trading. But we also faced a tough comparison quarter for Q2 2025. This included significant instrument module shipments to enable us to locally produce in China, which in the long term will make us more competitive. But that quarter last year was particularly tough to compare against. If we look across the APAC region, reagent sales grew strongly, particularly in Japan and Australia. And this is excellent news for us because this is recurring business; sales were also boosted by a UN tender win. As I mentioned at the start. We now look at sales by product line, and instruments really drove the quarterly results, up 7% to 113 million SEK. As I said, it was an all-time high for large instrument sales, particularly in the Americas. The primary driver here is automated workflows for midsize and large laboratory networks. The order intake in EMEA is still slightly affected by the concluded inventory adjustment from our main partner there. And there's a steady performance in APAC with sustained traction in key markets outside of China, as I mentioned. If we look at the reagents, sales increased by 11% to 42 million SEK in the quarter, and reagent sales were in line with the same quarter last year, despite temporary delays on shipments from our production site due to the recent heat wave in France. Due to excess temperatures, we had to requalify materials from the warehouse, and this led to some delayed orders which, had that not happened, would have posted higher growth in APAC. There was strong growth across all subregions, particularly in Japan and Australia. And then finally, if we look at software and other. The sales amounted to 46 million SEK in the quarter. It should be noted that the software sales are not completely synchronized with the instrument. Obviously we sell the instruments, but there is typically a lag or a delay, where software is then consumed once the instrument is actually installed at the customer site. Quarterly fluctuations in software sales have impacted the performance overall here. And then the other segment consists mainly of spare parts, consumables and currency effects. So if we move to slide six, just to summarize the overall picture for the quarter. Key takeaways. This quarter we delivered an increase in net sales of 4.5% to 201 million SEK. Sales increased organically by around 6% with a 1.1% headwind on FX. EBITDA delivered a result of 55 million SEK, which corresponds to a 27% EBITDA margin. And this is in line with typical returns, given the costs associated with the CEO transition. The commercial launch of the Bone Marrow Aspirate (BMA) Application marks an important milestone as we expand into specialized microscopy. We continue to progress the FDA registration process, and the aim is to obtain 510(k) market clearance in the US before year-end. From an innovation perspective, FPM technology, as I mentioned, has progressed significantly through our internal development phases. FPM will form the foundation of our next-generation hematology analyzers. This progress strengthens our confidence in FPM as a platform technology for future innovation beyond hematology in adjacent markets such as pathology and cytology. These are excellent markets to be able to penetrate. The results that we are seeing reinforce our confidence in the market opportunities we face, and they demonstrate progress in translating our investments in innovation into commercial results. As I step into the role of CEO, I'm committed to building on this momentum by combining our strong innovation portfolio with more focused commercial execution. And with that, I'd now like to open up to questions. I will be ably assisted by Monica today, so if there are any questions I can answer, I'm happy to do so. And anything that requires more information or is beyond my five-week knowledge gap, I will hand over to Monica. I am very happy to receive questions.

Operator
13:45 - 14:03

If you wish to ask a question, please dial pound key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial pound key six on your telephone keypad. The next question comes from Christian Lee from Pareto Securities. Please go ahead.

Christian Lee
14:05 - 14:32

Yes. Thank you and good morning. I have a couple of questions and I will take them one by one. The first is regarding the exceptionally high growth in the Americas. And since you already have a high large instrument penetration in North America, was this growth driven by Latin America or by replacement cycle activities?

Steve Ferguson
14:34 - 15:02

Okay. Thanks for the question, Christian. The main driver for sales here is robust demand for the larger instruments in the medium and large segment. The drivers here again were tender wins and instrument refreshes in those segments, and the LATAM and Canada business are showing promising growth within that. But the main driver here is that lab segment. Those two lab segments.

Christian Lee
15:07 - 15:21

Okay. Thank you. If I remember correctly, I believe you have almost 100% penetration rate in North America. So, how come you can show this kind of growth rate in the second quarter?

Steve Ferguson
15:22 - 16:00

I would say that we have a high market share in the large and medium lab segment. So there are refresh and tender windows that are coming up. They are continual. So there is a life cycle on laboratory systems that gives us an opportunity to win new business, but also to refresh. But there are other segments outside of that that are probably touching on commercial focus. I'd like to explore more. So the smaller labs where perhaps our partners aren't present, and there may be more opportunities for growth here in the future for us. It is by no means saturated. I think there is still room for growth in the Americas region.

Christian Lee
16:02 - 16:28

Okay. Perfect. Thank you. My second question is regarding EMEA with the inventory adjustment. And now that this has concluded at your main distributor, how do you see the Q3 demand trajectory? And could you also perhaps give us some color on the share of sales that this partner is representing? Thank you.

Steve Ferguson
16:31 - 16:59

Yeah. So, the share: we have a strong partnership with our main distributor partner, and the majority of our business goes through them. Quarter. The order book looks promising for EMEA. It looks like we have a strong order book for the third quarter overall, but we're confident that the inventory depletion has now been run down and we're seeing orders in Q3. Monica, if there's anything to add there.

Monica Johnson
17:01 - 17:11

No, that is correct. So, inventory readjustment has been completed and the orders are coming back to normal levels now in Q3.

Christian Lee
17:15 - 17:17

Perfect. Thank you very much. That is all for me.

Operator
17:21 - 17:25

The next question comes from Simon Larsson from Danske Bank. Please go ahead.

Simon Larsson
17:27 - 17:53

Yeah. Good morning. Maybe also following up on the Americas print. Just wondering if you are aware of any channel stuffing in this very strong second quarter and maybe how we should consider that. Yes, please outline the future for the second half and indicate if this trend is something to be extrapolated. Should we expect a more normalized pattern in the second half for what you see in the Americas?

Steve Ferguson
17:53 - 17:58

Yes. I missed a word there. Sorry. Could you repeat the word stocking?

Simon Larsson
17:59 - 18:11

Yeah. So, are you aware of any channel stuffing or stocking effects in the Americas? Yeah. Given the strong print, how should we think about it when we consider our estimates for the remainder of the year in America specifically.

Steve Ferguson
18:12 - 18:56

Yeah. So I would say there is no evidence there at the moment. Simon. If anything, it is the opposite with the inventory normalization, if that is the right word, that impacted us in EMEA. And there was also some of that in America as well. And we have seen units being consumed. So, as a response to this, we have had much stronger dialogue with our partners. And we have set up processes that will give us much clearer, much more transparent visibility into their inventory levels. So we are confident that the order book for both the Americas and EMEA will be robust for the second half of the year.

Simon Larsson
18:59 - 19:24

Okay, cool. That sounds reassuring. And also on the Bone Marrow Aspirate (BMA) Application, which I think you sold your first couple of units here in the quarter. Are you still sticking to your former statement on the Bone Marrow Aspirate (BMA) Application? I think it was one or perhaps two percentage points of incremental growth for the second half from that product, or what are your internal expectations for that product in the second half?

Steve Ferguson
19:26 - 20:03

Yeah. Thanks again. Salman. We maintain the same view regarding initial feedback; there is obviously a long lead cycle in in vitro diagnostics, especially in diagnostics. As customers evaluate new technology, they have evaluations on site and qualify the instruments and the analyzers on site. So there is a long lead cycle. But having said that, the news that is coming back from the market, the number of evaluations and the customer reactions is extremely encouraging. And we still hold our position that by year-end, the Bone Marrow Aspirate (BMA) Application sales should account for 1% to 2% growth. That is our target range.

Simon Larsson
20:06 - 20:26

Perfect, perfect. Also, in APAC and the reagent side of the business, we have seen a couple of strong quarters in a row. Now, I am just curious what drives that adoption? What kind of users, if you can name any countries and similar examples, to get a good grip of that business.

Steve Ferguson
20:26 - 21:23

Mhm. So the main customers in the quarter are anyone who is producing or staining microscope slides. So that could be any laboratory or any research institute. It could be partners that we are selling through. And the growth is encouraging. As you say, it is sustained now, or we are starting to see momentum in that area. And it's a role. It is a model for us to look at for the other regions. Looking at the countries specifically in APAC, it is Japan and Australia that are really driving the growth. And like I said earlier, this is pleasing because that is recurring business for us. So those are the two that I would highlight in that. And that is despite significant headwinds in China for not just CellaVision, but for the industry broadly. So to see that the regional growth in APAC is very, very encouraging.

Simon Larsson
21:26 - 21:39

Yeah, yeah. Are these pilot projects that have now transformed into recurring customers, or how would you describe that? Yeah. What has the development been like when it comes to that? Yeah.

Steve Ferguson
21:40 - 21:55

Maybe, Monica, you can add to this, but the business that we see coming from Japan and Australia in Q2. That is definitely recurring. And I think the majority of the sales elsewhere tends to be recurring. But Monica, if you want to comment on that.

Monica Johnson
21:55 - 22:06

Yeah, you are right. We have spent a lot of resources on really getting into those markets here in Japan and Australia. And it is recurring revenue.

Simon Larsson
22:11 - 22:42

Yeah. Good. Maybe a final one from my end to you, Steve, because I noticed in the CEO letter that you talked about commercial execution a couple of times. So I was just wondering what that entails for you. I mean, given the tight relationship with your main partner today, maybe one would think that there is not much you can tweak in the go-to-market strategy. Please correct me if I am wrong. I mean, what are you seeing when you speak about commercial execution, and what can be done better or more from CellaVision's side?

Steve Ferguson
22:43 - 24:16

Sure. Great question, Simon, I think. Firstly, let me talk about our major distribution partner. The fact that we want to be more commercially focused is actually a reflection that we want to invest more in that relationship. I think that partnership is successful for both parties. It has been a great relationship. And we want to make sure that we sustain that and nurture it. I think there is a lot more that we can do, and we are serving the customers that we jointly serve extremely well. But there are other segments out there, and other laboratory segments where perhaps our partner is not playing that I would like to get closer to. And that could in turn throw up more opportunities for the partnership. But I want to make sure that every laboratory everywhere in the world that has a microscope is aware of the CellaVision technology, and that is an opportunity for us to take more responsibility in that. Looking more at the horizon and really understanding the customer need more closely. But I would like to stress that we do that in partnership with our major partner globally. The other thing to talk about is that as we expand through Fourier Ptychographic Microscopy (FPM), there could be other segments outside of Hematology that we really want to get to know better. So that is what I mean when I talk about commercial execution. I want to ensure that we understand the end customer's needs and that we are continually evolving our solutions to meet those needs fully.

Simon Larsson
24:19 - 24:23

Yeah. Cool. Thanks so much for the answers. I will get back in queue.

Steve Ferguson
24:25 - 24:25

Thanks, Simon.

Operator
24:29 - 24:33

The next question comes from Ludvig Lundgren from Arctic Securities. Please go ahead.

Ludvig Lundgren
24:36 - 25:03

Hi. Thank you for taking my questions and congrats on the appointment, Steve. So I have a few questions and I will take them one by one. So, maybe just starting off with a bit of a clarification here on the destocking you saw on the instrument side in EMEA in Q2. If you are able to quantify approximately how much this affected the quarter, and also how much you can quantify the reagent delay in shipments in Q2.

Monica Johnson
25:08 - 25:58

I will start with that one. The first question on how much the EMEA inventory destocking impacted Q2. It was not that much. It was mainly in the beginning of April when we saw that it was still slow. But then throughout the quarter, we saw that the orders were coming back. So the impact was not that big in Q2. And when it comes to the reagent delay in France, it is a couple of million SEK that were delayed into Q3. If you remember, in Q1, there were some other delays that have now been resolved. That was the UN tender. So things happen between the quarters, but about a few MSEK were delayed due to the heat wave in France.

Ludvig Lundgren
26:00 - 26:20

Thank you. Very clear. And then also a bit of a follow-up on large labs in the Americas. I wonder if you have seen any change in lab investments or large lab investments and tender activity during the quarter. Because I know that Abbott guided for accelerated core lab demand in H2. Do you share that view? Um, yeah.

Steve Ferguson
26:23 - 26:40

I think, if I can just say, the results from our side would indicate that those segments in America are growing strongly. But we haven't seen anything specific that we would call out from an external perspective, as Abbott have done.

Ludvig Lundgren
26:44 - 27:00

Thanks, Claire. And then on the cost side, I note that admin expenses were up about 10% even after adjusting for the CEO transition costs. So, I wonder if there is anything you can call out there regarding any other non-recurring items.

Monica Johnson
27:03 - 27:10

There were some additional consultant costs that came in as part of the administrative costs this quarter.

Ludvig Lundgren
27:13 - 27:24

All right. So, if trying to dissect underlying admin costs, would you say that it's more flat year-over-year, or how should we think about that as we head into H2?

Monica Johnson
27:26 - 27:46

Yeah. There is some increase due to salary increases that took effect from April 1st for all personnel in the company. There have also been some investments, especially in the IT area, and those are going into administration costs as well. That could be more fluctuating throughout the quarters.

Ludvig Lundgren
27:49 - 28:14

All right. Very clear. Thanks. And then a final one just on the total R&D, including the capitalized portion, grew quite a bit here year over year, which I assume might relate to the upcoming U.S. launch of the Bone Marrow Aspirate (BMA) Application. launch of the Bone Marrow Aspirate (BMA) Application. So. So maybe help us understand how we should think about this as we head into H2. Is this a new level? We should kind of extrapolate, or how should we think about this number?

Monica Johnson
28:16 - 28:45

R&D costs, excluding capitalization, are increasing slightly. Exactly as you say, we are spending resources on the FDA applications and also increasing our focus on innovation. But if we then start thinking about what we capitalize, we will see higher capitalization starting from Q3. And due to the fact that we have some projects that are advancing in maturity, that will compensate for some of the increase.

Ludvig Lundgren
28:51 - 29:03

Okay, great. Thanks. And then if I can squeeze one more in just on the estimated timeline for the Bone Marrow Aspirate (BMA) Application launch in the U.S., is there any news there or regarding the FDA application?

Steve Ferguson
29:05 - 29:13

We are in line with expectations, Ludwig, that it should be there by year end. So we are in dialogue and the process is going according to plan.

Ludvig Lundgren
29:15 - 29:18

Okay, great. Thank you very much. I'll jump back into the queue.

Steve Ferguson
29:19 - 29:20

Thanks, Ludwig.

Operator
29:21 - 29:25

The next question comes from Elvin Roleder from DNB Carnegie. Please go ahead.

Elvin Roleder
29:27 - 30:16

Good morning, Steve and Monika. A lot of questions have been asked already, but maybe I will ask a follow-up on one of Simon's questions regarding the commercial execution part. I hear that you want to accelerate the partnership with Sysmex. But as a follow-up to that. Is there any kind of detail you can provide? Now, I know that it's early days for you, Steve. But are there any kinds of opportunities? If we look on a regional basis where you feel that CellaVision perhaps has been lacking a bit historically, where do you feel that you can accelerate either salespeople or support functions in order to capture a higher share of growth? I know that you've invested quite a bit in the Americas, but are there any regional white spots where you feel that you are able to accelerate the organization a bit, if you can comment?

Steve Ferguson
30:17 - 31:21

Yeah, great question and thank you for that. I think, firstly, the relationship with Sysmex is vital for us. I think it's a symbiotic relationship, and I believe there is a lot of value for both parties. Together, our combined value proposition is greater than the sum of the individual parts. If you look just at the results, the relationship in the Americas is particularly strong. And I think that is the role model for us. And that is the discussion that we are already having with Sysmex. And how can we win together more effectively using, for example, the Americas as the strongest model? As I mentioned earlier in response to Christian or Simon's question about market share in America. I still think there is more potential in the Americas that we can go after. And I think in every country we can be more effective together. And that is why we want to invest, take ownership, and take responsibility for our part in that, to really drive much more effective commercial activities.

Elvin Roleder
31:26 - 31:54

Great. Thank you. Maybe then a question on the Americas, regarding smaller instruments. For the second quarter now, I believe you mentioned that there have been some elevated inventory levels in the Americas for smaller instruments. Can you give some sort of outlook or guidance on when you expect these effects to normalize and when smaller instruments can pick up again in the region? Or how should we view that for H2 and onwards?

Steve Ferguson
31:56 - 32:16

Yeah. From what we are able to see. And again, Monica, please chip in if I misunderstood this, but from what we're seeing, we think that the inventory normalization has washed through. So, we did see consumption from their inventory in quarter two. And also we have an order book. We have orders already placed for Q3.

Elvin Roleder
32:21 - 32:46

Okay. Perfect. And then finally, for me, a nitty-gritty question or perhaps irrelevant, but you say that the quarter was charged with 6.9 million for the initial phase of the CEO transition. Should we expect any further CEO transition-related costs in Q3? Is that how should we think of that?

Steve Ferguson
32:47 - 33:18

Yeah. Thanks. I think the costs incurred so far are a mixture of the CEO severance, the recruitment costs, and other involved consultants. The discussion is still ongoing. So it is not possible to comment any further on that. This is obviously a transition period, but the costs associated with that first phase have come to 9 million in quarter two. At this point, I cannot really comment any further on that.

Ludvig Lundgren
33:19 - 33:20

Okay.

Elvin Roleder
33:21 - 33:25

Perfect. Thank you. I will get back in line. Thank you for answering my questions. Answering my questions.

Steve Ferguson
33:26 - 33:27

Thanks, Evan.

Operator
33:28 - 33:40

As a reminder, if you wish to ask a question, please dial the pound key on your telephone keypad. The next question comes from Christian Lee from Pareto Securities. Please go ahead.

Christian Lee
33:42 - 34:13

Yes. Thank you. I have a follow-up question regarding your R&D expenses. Monica, you mentioned that you expect the capitalization to increase in the third quarter. Is that in absolute terms compared to the second quarter? And could you also give us some color on how we should consider the total R&D investments, including the capitalization, starting from the third quarter? Thank you.

Monica Johnson
34:14 - 35:08

Mhm. Yes. So they will increase versus what we have seen now in Q1 and Q2. Capitalization has been quite low. We believe we will go back to levels where we were in the beginning of last year. And probably a little beyond that as well when it comes to capitalization, as we have some bigger projects now advancing through our different toll gates, which means that we are starting to capitalize them. And then your question was also about the total R&D costs. And there we see some increase versus previously. But that one is not huge. It is a gradual increase, as hiring more people into the organization takes more time; it is a more gradual increase. So there will be an impact on R&D costs, including the capitalization.

Christian Lee
35:12 - 35:13

Okay, great. Thank you.

Operator
35:18 - 35:24

There are no more questions at this time. So I hand the conference back to the speakers for any closing comments.

Steve Ferguson
35:26 - 36:34

Okay. Thanks, everyone, for joining the call this morning and for following us here at CellaVision. And thank you in particular to the four analysts who asked us questions. And before I close today, I'd like to thank all of the team at CellaVision for their very warm and patient welcome. Welcome as I get up to speed. As a new CEO, I want to thank in particular Simon Ostergaard, the outgoing CEO, who has been really working with me on a very professional and very smooth handover. And not just for this. I also want to thank Simon for his contribution over his five-year tenure as CEO at CellaVision. Simon's work and that of Zlatko before has built a tremendously strong company with huge opportunities for growth. And I'm really excited to be at the helm to help the company realize its potential going forward. Our next interim report will be published on the 29th of October 2026, and I look forward to commenting on that report with you then and taking your questions at that point. Thank you for joining us this morning and have a great day.

Continue to the webcast
Pierce Group, Audiocast, Q3'26
Language: English11/13/2026, 8:00 AM
Göran Dahlin Good morning, everyone, and welcome to Pierce Group's presentation of our Q3 2026 interim results. Next slide, please. I am Göran Dahlin, CEO of Pierce Group, and I am with Fredrik Kjellg…
Surgical Science Sweden, Audiocast, Q3'26
Language: English11/12/2026, 10:00 AM
Tom Englund Hi everyone, and welcome to this earnings call for Surgical Science for the third quarter of 2026. My name is Tom Englund. I am the CEO. And with me today is our CFO, Anna Ahlberg. I wil…
ExpreS2ion Biotech – Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 9:00 AM
ExpreS2ion is expected to release its Q3 2026 interim report on 12 November 2026. Later the same day at 10.00, ExpreS2ion’s CEO Bent U. Frandsen and CFO Keith Alexander will present the results and answer questions in a live online event.
Meko Services AB, Q3'26
Language: English11/12/2026, 8:00 AM
Pat Thank you. Good morning, and welcome to MEKO's presentation of the third quarter of 2026. I am here with our CFO, Christy Johansson, and I will begin with an overview of the quarter and some of th…
WeSports Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Unknown 1 It. Ted Sporre Welcome to our Q3 release presentation. As you know, we have already shared preliminary figures for sales and EBITDA for this quarter, but today we complete the picture. We wi…
Nordrest Holding, Audiocast, Q3'26
Language: Swedish11/12/2026, 8:00 AM
Thomas Dahlstedt Hej och välkomna! Vi ska idag presentera Nordrests senaste kvartal och tillika resultatet för perioden. Jag som pratar nu heter Thomas Dahlstedt och är grundare och tillika VD för bol…
Karnov Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Pontus Bodelsson Welcome, everyone, to Karnov Group's earnings conference, where we will present the outcome of the third quarter of 2026. Please go to slide two. I am Pontus Bodelsson, President and…
Fasadgruppen Group, Audiocast, Q3'26
Language: English11/12/2026, 7:15 AM
Magnus Blomberg Perfect. Good morning and welcome to the Fasadgruppen presentation of our results for the third quarter 2026. My name is Magnus Blomberg. You have met me before. I am the CFO of Fasadg…
Munters AB, CMD
Language: English11/11/2026, 1:00 PM
Lena Dauvergne Good. Good afternoon everyone, and a warm welcome to Stockholm, to ESSEX and to Montage Capital Markets Day 2026. Montage Capital Markets Day 2026. It is really good to see so many of y…
Cinclus Pharma, Audiocast, Q3'26
Language: English11/11/2026, 1:00 PM
Christer Ahlberg Thank you. Hello and welcome to the Cinclus Pharma third quarter 2026 earnings call. I am Christer Ahlberg, CEO of Cinclus Pharma, and with me today is our CFO, Magnus Christensen. We…
Proact IT, CMD
Language: English11/11/2026, 12:30 PM
Unknown 1 The world of data is constantly changing. Breaches are rising, and attacks are getting more advanced. Regulation drives the need for data sovereignty. Data has to be available. Critical busi…
Ferronordic AB, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Henrik Good morning, everyone, and welcome to our presentation of the third quarter of 2026. During the quarter, we saw higher earnings, and growing aftermarket revenue was up 15% to 1.2 billion Swedi…
BICO, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Anders Fogelberg Good morning, everyone, and welcome to BICO's earnings call for the third quarter of 2026. I am Anders Fogelberg, President and CEO of BICO. And joining me today is our Group CFO, Ewa…
Catena Media, Audiocast, Q3'26
Language: English11/10/2026, 5:00 PM
Manuel Stan Good afternoon. Good evening, everyone. Welcome to the Catena Media Q3 Interim Report. I am Manuel Stan and today I'm joined by our Chief Financial Officer, Michael Gerrow. Today we will b…
Ellos Group, Q3'26
Language: English11/10/2026, 8:00 AM
Hans Ohlsson Live. Good morning, everyone, and welcome to the second presentation for Ellos Group as a listed company. We have 45 minutes today for the presentation. And there is a hard stop. After th…
Scandic Hotels Group, Audiocast, Q3'26
Language: English11/10/2026, 8:00 AM
Jens Mathisen Thank you so much, and good morning, everyone, and thank you for joining us for the Q3 presentation. I am Jens Mathisen, CEO of Scandic. And joining me is our CFO, Pierre Carstensen. We…
Svevik Industri, Q3'26
Language: Swedish11/6/2026, 9:00 AM
Johan Hårdén Tack så mycket! Hello and welcome to this hearing regarding the Q3 2026 interim report. We have an agenda where we intend to introduce ourselves to all the new shareholders as well. Kort…
Attendo, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Martin Tivéus Good morning, everyone, and thank you for joining us. Today, we will present our results for the third quarter of 2026. I am pleased to announce that this is the strongest quarter for At…
Cavotec, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
David Pagels Good morning and welcome to Cavotec's Q3 2026 presentation. I am David Pagels, the CEO of Cavotec. And together with me today, I have our new CFO, Christoffer Robertsson. I would like to…
Fractal Gaming Group, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Jonas Good morning, everyone, and welcome to Fractal's Q3 2026 presentation. Today, we'll take you through our results, the progress that we've made, and our priorities ahead after a difficult first h…